Welcome to our dedicated page for Neoleukin Therapeutics news (Ticker: NLTX), a resource for investors and traders seeking the latest updates and insights on Neoleukin Therapeutics stock.
Neoleukin Therapeutics, Inc. (symbol: NLTX) is a cutting-edge biopharmaceutical company focused on the development of next-generation immunotherapies. Using advanced de novo protein design technology, Neoleukin creates synthetic proteins with specific pharmaceutical properties designed to treat cancer, inflammation, and autoimmune diseases.
In recent developments, Neoleukin has implemented a reverse stock split, approved by its stockholders at the 2023 Annual Meeting held on June 8, 2023, and executed by the Board on August 30, 2023. This reverse stock split reduces the number of shares of common stock from approximately 44,026,429 to about 8,805,285, while also adjusting the number of authorized shares from 100,000,000 to 20,000,000. While this adjustment affects all stockholders uniformly, it simplifies stock management without altering any stockholder’s ownership percentage, except for those receiving cash in lieu of fractional shares.
As of March 2023, Neoleukin restructured its operations to conserve capital. This strategic move was part of an overarching plan to streamline operations while focusing on its core competencies. The company continues to leverage its sophisticated computational methods to develop proteins with superior therapeutic benefits compared to native proteins. Neoleukin's innovation has positioned it as a leader in the biotechnology sector, providing advanced solutions for complex health challenges.
Furthermore, a proposed merger and its anticipated impacts on the company’s stock and listing on the Nasdaq Capital Market are key topics for investors. The merger is expected to result in a combined total of approximately 13,676,732 shares of outstanding common stock.
For more information, please visit the Neoleukin website or contact Neoleukin's investor relations and media teams at investors@neoleukin.com.
Neoleukin Therapeutics (NASDAQ: NLTX) announced a collaboration with Merck to evaluate NL-201, a de novo protein aimed at mimicking cytokines IL-2 and IL-15, in combination with Merck's KEYTRUDA® (pembrolizumab) for advanced solid tumors. The ongoing Phase 1 trial will enroll up to 132 patients to assess safety, pharmacokinetics, and antitumor activity. Previous preclinical studies indicated that this combination showed promising results, making it a key part of Neoleukin's NL-201 program. The trial is set to start in 2022.
Neoleukin Therapeutics (NASDAQ: NLTX) announced that CEO Jonathan Drachman will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The on-demand presentation will be accessible starting January 10 at 7:00 a.m. ET via Neoleukin's investors section. Neoleukin focuses on developing next-generation immunotherapies for cancer and autoimmune diseases using de novo protein design technology. Its lead product, NL-201, is an IL-2 and IL-15 agonist aimed at enhancing therapeutic efficacy.
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) presented promising preclinical data for NL-201 at the 63rd ASH Annual Meeting, indicating anti-myeloma activity and potential use in hematologic malignancies. The data demonstrated that NL-201 can prevent relapse in mouse models post-autologous stem cell transplant by enhancing cytotoxic CD8 T cells while reducing regulatory T cells. Additionally, NL-201 showed synergistic effects when combined with anti-PD-1 therapy in non-Hodgkin lymphoma models. A Phase 1 clinical trial for NL-201 in patients with hematologic conditions is planned for 2022.
Neoleukin Therapeutics (NASDAQ:NLTX) presented promising preclinical data on NL-201, a novel IL-2 and IL-15 dual agonist, at the SITC 2021 conference. NL-201 showed potential to enhance cancer-fighting T cells and natural killer cells without bias toward CD25-expressing cells. Key findings included its ability to convert 'cold' tumors to 'hot', driving anti-tumor activity and improving tolerability through intratumoral administration. The Phase 1 trial for NL-201 is ongoing, assessing safety and dosing with positive implications for cancer treatment.
Neoleukin Therapeutics (NASDAQ: NLTX) plans to participate in two upcoming investor conferences. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 16, 2021, from 3:20 to 3:50 p.m. EST, featuring a fireside chat format. Following that, the Piper Sandler 33rd Annual Virtual Healthcare Conference will take place on November 22, 2021, with sessions available on-demand from 10:00 a.m. EST. Presentations will be accessible on Neoleukin's website, and archived replays will be available for at least 30 days post-event.
Neoleukin Therapeutics reported its Q3 2021 financial results, highlighting progress in the NL-201 Phase 1 clinical trial for solid tumors, with interim data anticipated in 2022. The company intends to initiate a second Phase 1 trial for hematologic malignancies next year. Financially, Neoleukin's cash and equivalents decreased to $154.9 million, with a net loss of $15.4 million compared to $2.2 million in Q3 2020. R&D expenses rose to $9.9 million from $6.2 million year-over-year.
On October 1, 2021, Neoleukin Therapeutics (NASDAQ: NLTX) announced the acceptance of four abstracts for presentation at the Society for Immunotherapy of Cancer’s 36th Annual Meeting, scheduled for November 10-14, 2021. The presentations will focus on NL-201, a novel IL-2/IL-15 agonist in phase 1 clinical development, highlighting its potential to activate tumor microenvironments and demonstrate antitumor activity. Key data will include NL-201’s effects on tumor growth in preclinical models and its activity in combination therapies.
Neoleukin Therapeutics announced promising results for its protein decoy NL-CVX1, which effectively prevents SARS-CoV-2 infection across various viral variants. In a recent presentation at IDWeek 2021, researchers revealed that a single intranasal dose of NL-CVX1 protects transgenic mice from acute infection and retains immunity after a month. The findings indicate NL-CVX1's strong efficacy against SARS-CoV-2 and its variants, supporting the potential of Neoleukin's advanced de novo protein design technology.
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) announced the appointment of Bill Arthur, Ph.D., as Vice President and Head of Research, effective September 9, 2021. Dr. Arthur brings a decade of experience from Seagen, where he led cancer biology and directed therapeutic research. His expertise will be crucial in advancing Neoleukin's innovative de novo protein technology. Neoleukin is focused on developing next-generation immunotherapies targeting cancer and autoimmunity, with its lead candidate, NL-201, aiming to enhance tolerability and efficacy.
Neoleukin Therapeutics, a biopharmaceutical company focused on computational protein design, announced that CEO Jonathan Drachman will present a corporate overview at the H.C. Wainwright 23rd Annual Global Life Sciences Conference from September 13-15, 2021. A pre-recorded presentation will be available on-demand starting at 7:00 am ET on September 13, accessible via their investors section online. Neoleukin's lead product candidate, NL-201, is designed to enhance cancer treatment by combining IL-2 and IL-15 agonist properties.
FAQ
What is the market cap of Neoleukin Therapeutics (NLTX)?
What does Neoleukin Therapeutics, Inc. do?
What is the recent reverse stock split about?
How does the reverse stock split affect stockholders?
Why did Neoleukin restructure its operations?
What are the notable technologies used by Neoleukin?
What is the impact of the proposed merger on Neoleukin's stock?
How can investors contact Neoleukin Therapeutics?
What is the significance of the de novo protein design technology?
Does the reverse stock split affect the company’s Nasdaq listing?
Where can I find more information about Neoleukin's recent developments?
